BROOKFIELD, Conn., March 18, 2025 /PRNewswire/ -- ROMTech, creator of the PortableConnect® Adaptive Telemed Technology and leader in rehabilitation medicine, has...
WAYNE, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and...
Toronto, Ontario--(Newsfile Corp. - March 17, 2025) - At the request of the Canadian Investment Regulatory Organization, Quantum BioPharma Ltd....
Nominations Open March 24 for $100,000 Annual Award Made Possible by the Linda and Mike Mussallem Foundation MOUNTAIN VIEW, Calif.--(BUSINESS...
-- Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new...
New executive hires to drive enterprise strategy and symplr Operations Platform advancement HOUSTON, March 13, 2025 /PRNewswire/ -- symplr®, a...
DALLAS, March 11, 2025 /PRNewswire/ -- Homecare Homebase℠(HCHB), the leading software provider for home-based care, is highlighting how Optimal Home...
Advantum is named to the 21st Annual Best Places to Work in Kentucky list for 2025. LOUISVILLE, K.Y., March 11,...
ALAMEDA ISLAND, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- genXtraits Inc. (genXtraits) and Norfolk Healthy Produce Inc. (NHP) today announced...
Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as...
Highly accomplished franchise development leader with over 20 years of experience to lead growth SCOTTSDALE, Ariz., March 11, 2025 (GLOBE...
O2X Human Performance and Building Homes for Heroes Partner on Integrated Health Workshop LA VERNIA, Texas, March 10, 2025 /PRNewswire/ --...
LAS VEGAS, March 9, 2025 /PRNewswire/ -- C-suite leaders from Houston Methodist and Health Data Analytics Institute (HDAI) will be speaking at...
Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also...
Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease...
ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and...
A Former Health System CEO, Mr. Statuto Has Over 30 Years of Leadership Experience CHARLES TOWN, W.V., March 7, 2025...
PORTLAND, Maine, March 6, 2025 /PRNewswire/ -- MedRhythms today announced that MR-005, the company's neurorehabilitation system to support gait rehabilitation...
COLUMBUS, Ohio, March 6, 2025 /PRNewswire/ -- Today, clinical trials dramatically underrepresent patients who live in rural areas of the...
FAIRFAX, Va., March 4, 2025 /PRNewswire/ -- Team Goldbelt, comprised of Goldbelt Apex, LLC, Knowesis, Inc., and zCore Business Solutions...